atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder.

The initial patients were treated by Dr. Thomas Jones, Cardiac Catheterization Laboratory Director at Seattle Children’s Hospital (Seattle, WA), Dr. Scott Lim, Medical Director of the Advanced Cardiac Valve Center at the University of Virginia (Charlottesville, VA) and Dr. Thomas Forbes, Director of Cardiac Catheterization Laboratory at Children’s Hospital of Michigan (Detroit, MI). The prospective, single-arm study will enroll up to 250 patients at multiple sites globally. Primary endpoints will be compared with established performance goals for previously FDA-approved transcatheter ASD occluders.

“I am pleased to be a part of this study and advance therapy options for septal defects that leave a minimal footprint behind. The reSept ASD Occluder implanted easily and had a successful outcome with no residual shunts,” commented Dr. Jones. “We look forward to continuing enrollment and further validation of this promising technology.”

Current ASD occluders have metallic frames that can place patients at risk for complications and prohibit future transseptal interventions. Initial clinical experience demonstrates effective closure of the ASDs treated with the company’s device.1

“The metal-free frame of the reSept ASD Occluder provides a low-profile that over time is replaced by the patient’s tissue, leaving minimal implant behind and restoring a more natural septum when compared to current occluder devices,” stated Saibal Kar, MD, Interventional Cardiology at the Los Robles Regional Medical Center in Thousand Oaks, California and Co-Principal Investigator of the IDE trial. “This provides a unique opportunity for physicians to effectively address ASDs while being mindful of our patient’s potential need for subsequent transseptal procedures.”

“I am pleased to have such a strong start to this important pivotal trial and it is incredibly exciting to have the participation of so many leading institutions,” said Laurent Grandidier, CEO of atHeart Medical. “I commend the team’s diligence to expanding the body of evidence supporting our reSept device and dedication to delivering this lifesaving innovation to patients around the world.”

A prospective, single-arm, global multi-site clinical investigation study that will enroll a total of up to 250 patients. The study aims to demonstrate the safety and efficacy of the reSeptâ„¢ ASD Occluder for treating clinically significant secundum ASD with a transcatheter approach as compared to pre-defined performance goals from other commercially available occluder devices.

Source: Company Press Release